U.S. Marine and Shipping Stock News

Amdocs recently reported fourth-quarter and full-year results, with quarterly revenue of US$1.15 billion and full-year net income rising to US$564.7 million, even as sales saw a year-over-year decline. Growth in managed services, strong cloud adoption, and the expansion of generative AI initiatives are establishing Amdocs as a significant technology partner for leading global telecom operators. We'll examine how Amdocs' rapid expansion in multi-year AI and cloud partnerships influences its...

CACI International recently reported first quarter fiscal 2026 financial results that exceeded Wall Street expectations, with adjusted diluted earnings per share of US$6.85 and revenue coming in ahead of forecasts. This performance prompted eleven analysts to raise their earnings estimates, reflecting broad confidence in the company’s ability to deliver growth despite complex market conditions. We’ll explore how this combination of strong financial results and rising analyst optimism could...

RadNet reported record third quarter 2025 results, posting revenue of US$522.87 million and net income of US$5.42 million, alongside raising its full-year guidance for both Imaging Center and Digital Health segments. Integration of the iCAD acquisition and a surge in digital health revenue highlight RadNet’s focus on technological expansion and operational efficiency within advanced diagnostics. Next, we’ll explore how RadNet’s raised outlook and digital health momentum impact its long-term...

In the past week, Trimble unveiled a suite of advancements across its software platforms at the annual Dimensions User Conference, introducing new AI-driven features for construction management, expanding integrations to reinforce its cloud ecosystem, and announcing the global rollout of enhanced design-sharing capabilities in Trimble WorksManager. These innovations further solidify the company's position in enabling collaboration and automation across the construction and geospatial...

Jazz Pharmaceuticals (JAZZ) has drawn fresh attention after reporting strong third-quarter earnings, revising its 2025 guidance, and confirming FDA approval for Modeyso in a challenging brain tumor indication. See our latest analysis for Jazz Pharmaceuticals. Jazz Pharmaceuticals’ momentum has picked up steam in recent months, driven by robust third-quarter earnings, higher financial guidance for 2025, and the FDA’s accelerated approval for Modeyso in a difficult brain cancer indication...

Wondering if Fiserv is a golden opportunity or a value trap? You are not alone, as many investors are asking the same question with its price shifts catching attention. Fiserv's shares recently dipped slightly by 0.3% this week, but the stock has seen a dramatic drop of 47.6% over the past month and is now down 70.0% in the past year. This could signal changing perceptions of growth or risk. Market confidence in Fiserv has been shaped by sector-wide fintech turbulence and regulatory...

GitLab (GTLB) just published its Global DevSecOps report, spotlighting the real-world impact of AI on software development. The study explores how faster coding brings new compliance hurdles and fragmented workflows. See our latest analysis for GitLab. GitLab’s latest report builds on a run of product launches and business updates, but investors have had a bumpy ride lately. Despite upbeat news about recurring revenue and platform growth, the 1-year total shareholder return is -22.4%,...

Outset Medical recently reported third quarter results, showing revenue of US$29.43 million and a reduced net loss of US$17.84 million compared to the previous year, while also lowering its annual revenue guidance for 2025. New research presented at the American Society of Nephrology's 2025 Kidney Week highlighted strong real-world outcomes for the Tablo system, including a large reduction in complications and high staff satisfaction across 1 million treatments in approximately 750...

Krystal Biotech (KRYS) just posted third quarter earnings that far outpaced last year. The company reported a sharp jump in net income and earnings per share for both the quarter and year-to-date. This strong performance quickly caught investors’ attention. See our latest analysis for Krystal Biotech. After this earnings jump, Krystal Biotech's share price quickly reflected renewed optimism, notching a 29.71% share price return year-to-date and a strong 35.93% gain over the last 90 days...

First Interstate BancSystem (FIBK) just wrapped up a strong third quarter, reporting year-over-year growth in both net income and net interest income. The bank's improved credit quality and completion of its share repurchase program help round out the positive news for investors. See our latest analysis for First Interstate BancSystem. On the back of its upbeat earnings and shareholder-friendly moves, First Interstate BancSystem’s share price has gained 6.8% over the past month, contributing...

Elanco Animal Health (ELAN) just released its third quarter results and updated financial guidance for 2025, giving investors a lot to digest. The company reported higher sales but a swing to a net loss, with projections for bigger losses in spite of increased revenue. See our latest analysis for Elanco Animal Health. Elanco Animal Health has certainly attracted attention lately, with its updated outlook and recent debt refinancing adding to the buzz. The momentum is hard to miss, as the...

Ford Motor (F) is reconsidering its approach to electric vehicles, as reports suggest the company may stop production of its F-150 Lightning pickup due to weak demand, supply disruptions, and continued losses. This shift reflects a broader reevaluation of Ford’s electric vehicle strategy in light of changing industry trends. See our latest analysis for Ford Motor. Ford’s recent EV shakeup comes on the heels of a remarkable run in its share price, with the stock up 16.6% over the past month...

Some Guardant Health, Inc. ( NASDAQ:GH ) shareholders may be a little concerned to see that the Chief Legal Officer...

On November 12, 2025, Semtech Corporation announced its Unified Software Platform (USP) for LoRa Plus devices, enabling advanced multi-protocol support on a single hardware platform and eliminating the need for separate hardware variants for different wireless protocols. This platform streamlines deployment and manufacturing for clients by allowing flexible protocol selection while protecting software investments across hardware generations. We'll explore how Semtech's multi-protocol USP...

Babcock & Wilcox Enterprises (NYSE:BW) just landed a $1.5 billion deal to deliver power infrastructure for a large AI data center. This signals a significant step into the growing tech-driven energy market. See our latest analysis for Babcock & Wilcox Enterprises. The share price of Babcock & Wilcox Enterprises has rocketed, posting an eye-catching 111.8% return over the past month and an impressive 295.4% gain so far this year. This renewed momentum follows the company’s entry into the...

Shares of U.S. Physical Therapy (USPH) have struggled over the past month, falling 16%. The stock is down 17% for the past year. However, underlying revenue and net income have continued to post positive annual growth, which might catch investors’ attention. See our latest analysis for U.S. Physical Therapy. After tumbling more than 15% in the past month, U.S. Physical Therapy's share price is clearly losing momentum, even as the company posts steady revenue and net income gains. Over the...

Microchip Technology Incorporated ( NASDAQ:MCHP ) will pay a dividend of $0.455 on the 9th of December. This means the...

Despite posting some strong earnings, the market for Sterling Infrastructure, Inc.'s ( NASDAQ:STRL ) stock hasn't moved...

Clarivate (CLVT) just posted third quarter results, narrowing its net loss and showing sales growth compared to last year. The company also raised its full-year revenue outlook, which is encouraging for investors tracking its turnaround. See our latest analysis for Clarivate. After a tough start to the year, Clarivate’s share price has regained some momentum, rising nearly 3% in the past week after management delivered better-than-expected third quarter earnings and lifted their full-year...

Raytheon recently announced it signed a Memorandum of Understanding with Avio to help establish a solid rocket motor facility in the United States, which will serve Raytheon and other customers as a vertically integrated merchant supplier with preferred access for Raytheon. This collaboration is expected to bolster domestic manufacturing capabilities for advanced defense components and strengthen both companies' supply chain resilience to meet growing global defense demand. We'll explore how...

Recently, Schrödinger reported third quarter results showcasing robust year-over-year revenue growth driven by both software and drug discovery segments, alongside revised 2025 guidance and a narrowed quarterly net loss. Copernic Catalysts, in collaboration with Schrödinger, announced surpassing a major technical milestone for the Neptune ammonia catalyst, highlighting significant potential industrial and environmental benefits. We'll explore how this advancement in ammonia catalyst...

Ionis Pharmaceuticals (IONS) shares have seen positive momentum lately, catching the eye of investors seeking growth in biotech. With strong annual revenue and net income trends, the company is drawing attention as industry dynamics continue to evolve. See our latest analysis for Ionis Pharmaceuticals. Ionis Pharmaceuticals’ share price has surged 108.85% year-to-date, fueled by promising pipeline developments and renewed optimism around biotech innovation. Long-term total shareholder returns...

United States Lime & Minerals just released its third quarter earnings, showing steady growth in both sales and net income compared to last year. The company also announced its regular quarterly dividend, highlighting consistent shareholder returns. See our latest analysis for United States Lime & Minerals. United States Lime & Minerals has seen some bounce in its share price lately, with a 7.3% climb over the past week hinting at renewed momentum following its strong quarterly results and...

Fortune Brands Innovations (FBIN) just posted its third quarter results, showing a noticeable drop in net income and earnings per share compared to last year. Sales edged down slightly as well. The company’s full-year guidance remains unchanged. See our latest analysis for Fortune Brands Innovations. After a weak quarter and little growth projected ahead, Fortune Brands Innovations’ stock has seen momentum fade. The 1-year total shareholder return is -34.95% and the year-to-date share price...